Overview

Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

Status:
Completed
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Dacarbazine
Endostatins
Temozolomide